Hosted on MSN

Compass Pathways gains after FDA clears IND for PTSD trial of COMP360

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...
Times Argus

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...
Healio

FDA accepts IND for synthetic psilocybin therapeutic to treat PTSD

Please provide your email address to receive an email when new articles are posted on . The acceptance paves the way for a pending phase 2b/3 clinical trial of COMP360 in PTSD. The manufacturer plans ...
Seeking Alpha

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression - Slideshow

The following slide deck was published by COMPASS Pathways plc in conjunction with this event.